U.S. Pharmacopeia Acquires Stratix Labs

Paine Schwartz Partners Makes Strategic Investment in Sterilex

April 27, 2021

Manufacturing

Paine Schwartz Partners has made a strategic growth investment through its Food Chain Fund V in Sterilex, a Hunt Valley, Maryland-based developer of proprietary antimicrobial and biofilm-control products serving food processing, animal health and water treatment markets. The investment will support Sterilex's product development, geographic expansion and scaling of its food safety platform; financial terms were not disclosed.

HGS BioScience Acquires Pharmgrade

January 13, 2026

Agriculture

Paine Schwartz Partners–backed HGS BioScience has acquired Pharmgrade, an Idaho-based developer of microbial consortium products, to strengthen its microbial capabilities and expand its integrated biologicals platform. The deal enhances HGS's R&D, formulation and manufacturing depth and helps scale Pharmgrade’s microbial technologies to retailers and growers across North America.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

Spectris plc Acquires MicroStrain Sensing Systems Business

June 19, 2023

Manufacturing

Spectris plc has signed a purchase agreement to acquire MicroStrain Sensing Systems Business for $37.6 million. MicroStrain, based in Williston, Vermont, reported unaudited revenue of $15.4 million for the year ended June 2022 and will be integrated into Spectris Dynamics to strengthen Spectris' sensor offering and North American presence; the deal is expected to close in the third quarter subject to regulatory approval.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Bora Pharmaceuticals Acquires Upsher-Smith Laboratories

August 5, 2025

Pharmaceuticals

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.